Long-term follow up of single dose high-dose rate brachytherapy (HDR BT) for localised prostate cancer has revealed higher than expected rates of biochemical and local failure. This study aimed (i) to investigate the pattern of relapse within the prostate with reference to the initial site of disease in those patients; and (ii) to examine if […]
Intravesical Bacillus Calmette-Guérin (BCG) is the gold standard for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC), but availability is limited by global shortages. We present the first North American clinical experience using intravesical hyperthermia (HIVEC) with high-dose mitomycin C (MMC) during BCG shortage.
While numerous current clinical trials are testing novel salvage therapies (ST) for patients with recurrent nonmuscle invasive bladder cancer (NMIBC) after bacillus Calmette-Guérin (BCG), the natural history of this disease state has been poorly defined to date.
To compare trimodality therapy (TMT) versus radical cystectomy (RC) and develop GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) for treatment of muscle-invasive bladder cancer (MIBC).
Ashish Kamat: Hello and welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from Houston, MD Anderson Cancer Center. And it’s my pleasure to welcome a friend and a colleague, Bernie Bochner, who is an Attending Surgeon at Memorial Sloan Kettering Cancer Center. Dr. Bochner obviously needs no introduction in this field. He […]
As treatment paradigms for prostate cancer have drastically changed over the past decade and most low-grade cancers are now safely monitored with active surveillance, the need for effective screening tools that adequately risk-stratify patients prior to considering prostate biopsy is more important than ever. Liquid biomarkers 4Kscore® and ExosomeDxTM were developed to identify patients at […]
San Francisco, CA (UroToday.com) — A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.
Purpose To explore the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in high risk prostate cancer (HRPCa) in a consortium of seven institutional phase II trials and prospective registries. Methods and materials Individual patient data were pooled for 344 patients with a minimum follow-up of 24 months. Biochemical recurrence-free survival (BCRFS) and distant metastasis-free […]
The EAU Guidelines Office is looking for a new chairperson to lead the office. Current Guidelines Office chairman Prof. James N’Dow has joined the EAU Executive as Adjunct Secretary General-Elect, awaiting full confirmation at the next General Assembly. Within the EAU structure, the Guidelines Office belongs to the EAU’s Education offices. The Guidelines Office comprises a […]
Controversial effectiveness of chemotherapy and still poor prognosis prompt us to find better treatment options. This study targeted at investigating whether adding radiotherapy based on chemotherapy can effectively improve the prognosis of patients, especially for advanced penile cancer.
